Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy

scientific article published on 23 February 2012

Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/STROKEAHA.111.643072
P932PMC publication ID3314718
P698PubMed publication ID22363056

P50authorJoAnn E. MansonQ6204013
Per Morten SandsetQ38544475
Mary CushmanQ40845084
Lisa W. MartinQ48633764
Lewis KullerQ88077314
P2093author name stringJohn Lynch
Karen C Johnson
Jan Rosing
Jacques E Rossouw
Mary Pettinger
Frits Rosendaal
Kamakshi Lakshminarayan
Jose G Merino
Sylvia Wasserthal-Smoller
P2860cites workClassification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke TreatmentQ22306370
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trialQ27860743
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trialQ28196294
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone TrialsQ28213284
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trialQ29615226
Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of AtherosclerosisQ37442669
Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good?Q37800316
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control studyQ43043857
Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort studyQ43260471
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trialQ43795711
Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy?Q44683726
Estrogen plus progestin and risk of venous thrombosisQ45092058
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitorQ46859775
Activated protein C resistance and acute ischaemic stroke: relation to stroke causation and age.Q48783051
Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patientsQ50898099
An enzyme linked immunosorption assay for tissue factor pathway inhibitor.Q51573391
Mechanisms of thrombosis related to hormone therapy.Q51821384
Venous Thrombosis and Conjugated Equine Estrogen in Women Without a UterusQ57452111
Tissue Factor Pathway InhibitorQ59275517
Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patientsQ70897387
A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1Q73515193
The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trialQ73926487
Acquired APC resistance and oral contraceptives: differences between two functional testsQ77418374
Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosisQ78863061
Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and strokeQ80827978
TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complicationsQ81628027
Effects of conjugated equine estrogen on stroke in the Women's Health InitiativeQ83348929
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectactivated protein C resistanceQ296104
drotrecogin alfaQ412888
P304page(s)952-957
P577publication date2012-02-23
P1433published inStroke JournalQ7624282
P1476titleTissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy
P478volume43

Reverse relations

cites work (P2860)
Q36602044Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis
Q48608361Haemostatic factors do not account for worse outcomes from ischaemic stroke in patients with higher C-reactive protein concentrations.
Q33842161Hemostasis and alterations of the central nervous system
Q38085783Mechanisms of hormonal therapy related thrombosis
Q37052531Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen
Q40439101The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women
Q36520556Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy
Q48465547Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation.

Search more.